R1 RCM (NASDAQ:RCM) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of R1 RCM (NASDAQ:RCM) in a research note published on Friday, Benzinga reports. They currently have a $14.30 price target on the healthcare provider’s stock.

Several other equities research analysts have also recently issued reports on the company. Stephens cut R1 RCM from an overweight rating to an equal weight rating in a research note on Thursday, August 1st. Leerink Partnrs lowered shares of R1 RCM from a strong-buy rating to a hold rating in a report on Thursday, August 1st. TD Cowen restated a hold rating and issued a $14.30 price objective (down from $20.00) on shares of R1 RCM in a report on Monday, August 5th. Morgan Stanley cut shares of R1 RCM from an overweight rating to an equal weight rating in a research report on Thursday, August 8th. Finally, Jefferies Financial Group lowered shares of R1 RCM from a buy rating to a hold rating in a report on Thursday, August 1st. Thirteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, R1 RCM has an average rating of Hold and an average target price of $15.41.

R1 RCM Trading Up 0.1 %

Shares of RCM stock opened at $14.19 on Friday. The company’s 50-day moving average price is $14.01 and its 200-day moving average price is $13.04. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.77. The stock has a market cap of $5.98 billion, a price-to-earnings ratio of -177.38 and a beta of 0.85. R1 RCM has a twelve month low of $8.87 and a twelve month high of $15.12.

R1 RCM (NASDAQ:RCM) last posted its earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $633.10 million. R1 RCM had a negative net margin of 1.68% and a negative return on equity of 1.44%. The firm’s revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts predict that R1 RCM will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RCM. Capital International Investors lifted its stake in R1 RCM by 0.8% in the fourth quarter. Capital International Investors now owns 8,343,199 shares of the healthcare provider’s stock worth $88,188,000 after acquiring an additional 67,485 shares during the last quarter. Sea Cliff Partners Management LP acquired a new position in shares of R1 RCM during the 4th quarter worth about $18,459,000. First Light Asset Management LLC acquired a new position in R1 RCM in the fourth quarter valued at approximately $8,625,000. Caas Capital Management LP acquired a new position in shares of R1 RCM in the 4th quarter valued at $148,000. Finally, Bridgefront Capital LLC boosted its stake in R1 RCM by 213.6% in the fourth quarter. Bridgefront Capital LLC now owns 32,266 shares of the healthcare provider’s stock valued at $341,000 after acquiring an additional 21,978 shares in the last quarter. 61.10% of the stock is currently owned by hedge funds and other institutional investors.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.